Utilizing Advanced Tools to Minimize the Burden of CMV in Transplant RecipientsActivity Evaluation and Credit Application Survey

1.Among D+/R- solid organ transplantations, which of the following is at lowest risk of CMV?

Lung

Kidney

Small bowel

Pancreas

2.Which of the following statements is true regarding an antiviral prophylaxis approach to preventing CMV post-transplantation?

Clinical trials fail to demonstrate definitive success of prophylaxis in preventing CMV.

Currently available antiviral agents used in prophylaxis are generally safe and well tolerated.

Viremia and CMV disease often develop once prophylaxis is discontinued.

Extending prophylaxis to six months has no impact on the incidence of late-onset CMV disease compared to 3 months of prophylaxis.

3.Which of the following tools has been used to characterize CMV-specific T cells as a means to predict patient response to CMV reactivation and infection?

NMR spectroscopy

ELISPOT

PCR

BAL

4.When compared to placebo, the use of letermovir for prophylaxis in HSCT recipients has demonstrated:

Significant reduction in CMV infection

No difference in all-cause mortality

Significantly longer median time to engraftment

Significant increase in graft-versus-host disease

5.Which of the following is the leading risk factor for CMV resistance?

Prolonged exposure to ganciclovir/valganciclovir

Liver transplantation

Tissue rejection within 3 months post-transplantation

Co-infection with adenovirus

6.Ganciclovir-resistant strains of CMV commonly have mutations is which of the following genes?

UL16

UL83

UL97

UL128

Utilizing Advanced Tools to Minimize the Burden of CMV in Transplant Recipients

Activity Evaluation and Credit Application

Post Test